StockNews.com Initiates Coverage on ProPhase Labs (NASDAQ:PRPH)

Research analysts at StockNews.com started coverage on shares of ProPhase Labs (NASDAQ:PRPH) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the stock.

ProPhase Labs Stock Performance

Shares of PRPH opened at $0.26 on Friday. The stock’s 50-day simple moving average is $0.65 and its 200 day simple moving average is $1.73. The stock has a market capitalization of $6.28 million, a price-to-earnings ratio of -0.21 and a beta of -0.30. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.33 and a current ratio of 1.47. ProPhase Labs has a 52-week low of $0.26 and a 52-week high of $7.48.

Institutional Investors Weigh In On ProPhase Labs

A number of large investors have recently made changes to their positions in the business. Sheets Smith Wealth Management bought a new stake in shares of ProPhase Labs in the 4th quarter worth approximately $158,000. HighTower Advisors LLC grew its position in shares of ProPhase Labs by 18.3% in the 3rd quarter. HighTower Advisors LLC now owns 179,045 shares of the company’s stock worth $434,000 after buying an additional 27,673 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in shares of ProPhase Labs by 9.2% in the 3rd quarter. Geode Capital Management LLC now owns 160,735 shares of the company’s stock worth $389,000 after buying an additional 13,590 shares during the last quarter. 9.45% of the stock is currently owned by institutional investors.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.